|Application ||WB, E|
|Other Accession||NP_079383, 156151389|
|Reactivity||Human, Mouse, Rat|
|Calculated MW||26 kDa|
|Application Notes||MYCT1 antibody can be used for detection of MYCT1 by Western blot at 1 - 2 µg/mL.|
|Target/Specificity||MYCT1; At least two isoforms of MYCT1 are known to exist; this antibody will detect both isoforms.|
|Reconstitution & Storage||MYCT1 antibody can be stored at 4℃ for three months and -20℃, stable for up to one year. As with all antibodies care should be taken to avoid repeated freeze thaw cycles. Antibodies should not be exposed to prolonged high temperatures.|
|Precautions||MYCT1 Antibody is for research use only and not for use in diagnostic or therapeutic procedures.|
|Function||May regulate certain MYC target genes, MYC seems to be a direct upstream transcriptional activator. Does not seem to significantly affect growth cell capacity. Overexpression seems to mediate many of the known phenotypic features associated with MYC, including promotion of apoptosis, alteration of morphology, enhancement of anchorage-independent growth, tumorigenic conversion, promotion of genomic instability, and inhibition of hematopoietic differentiation (By similarity).|
|Cellular Location||Nucleus. Note=Expressed in nuclei of hepatocellular carcinoma cell line BEL-7402 cells|
|Tissue Location||Down-regulated in gastric cancer tissues.|
Thousands of laboratories across the world have published research that depended on the performance of antibodies from Abgent to advance their research. Check out links to articles that cite our products in major peer-reviewed journals, organized by research category.
email@example.com, and receive a free "I Love Antibodies" mug.
Provided below are standard protocols that you may find useful for product applications.
MYCT1 Antibody: MYCT1 was initially identified as a novel target of the c-Myc oncogene in myeloid cells. It is a widely expressed nuclear protein whose overexpression can promote apoptosis, alteration of morphology, enhancement of anchorage-independent cell growth, tumorigenic conversion, promotion of genomic instability, and inhibition of hematopoietic differentiation. MYCT1 binds to the promoters of several c-Myc-regulated genes and it has been suggested that the phenotypes seen in MYCT1-overexpressing cells are a result of the deregulation of these genes. RUNX1-ETO, a fusion protein made up of RUNX1 and ETO, is thought to deregulate the proliferation and responsiveness of human hematopoietic progenitor cells downstream of MYCT1.
Yin X, Grove L, Rogulski K, et al. Myc target in myeloid cells-1, a novel c-Myc target, recapitulates multiple c-Myc phenotypes. J. Biol. Chem. 2002; 277:19998-20010.
Rogulski KR, Cohen DE, Corcoran DL, et al. Deregulation of common genes by c-Myc and its direct target, MT-MC1. Proc. Natl. Acad. Sci. USA 2005; 102:18968-73.
Liddiard K, Burnett AK, Darley RL, et al. RUNX1-ETO deregulates the proliferation and growth factor responsiveness of human hematopoietic progenitor cells downstream of the myeloid transcription factor, MYCT1. Leukemia 2012; 26:177-9.
If you have used an Abgent product and would like to share how it has performed, please click on the "Submit Review" button and provide the requested information. Our staff will examine and post your review and contact you if needed.
If you have any additional inquiries please email technical services at firstname.lastname@example.org.